Biotechnology News and Research

RSS

Australian TGA approves Acetadote for treatment of paracetamol poisoning

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd. today announced that Acetadote® (acetylcysteine) Injection has been granted regulatory approval for marketing and sale in Australia. Acetadote, an injectable drug used to treat acetaminophen (paracetamol) overdose, was approved by the Therapeutic Goods Administration (TGA), the government agency responsible for regulating drugs and medical devices in Australia.

12 May 2010

Genmab reports revenues of DKK 107M for first-quarter 2010

Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).

12 May 2010

Tianyin third-quarter revenue up 60%

Tianyin Pharmaceutical Co., Inc.,, a biopharmaceutical company that specializes in the modernized traditional Chinese medicine and branded generics today announced fiscal results for its third quarter ended March 31, 2010.

12 May 2010

Phase IIb study of EVP-6124 initiated in patients with Alzheimer's disease

EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer's disease.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Compugen discovers CGEN-928 as antibody drug target for treatment of multiple myeloma

Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently completed studies, CGEN-928, a membrane protein which previously had no known function or potential clinical utility, demonstrated broad expression in human multiple myeloma tumor cells, including drug resistant and aggressive primary tumor cell lines.

12 May 2010

Bionovo reports net loss of $4.7M for first-quarter 2010

Bionovo, Inc. today announced first quarter highlights and financial results for the three months ended March 31, 2010.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Microfluidics International first-quarter revenue up 21%

Microfluidics International Corporation, today reported unaudited financial results for the first quarter ended March 31, 2010.

11 May 2010

Amorfix, Epitomics collaborate to develop high-affinity monoclonal antibodies against cancer targets

Amorfix Life Sciences and Epitomics, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes (DSEs) on misfolded proteins with their proprietary ProMIS(TM) computational platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies (mAbs).

11 May 2010

China Pharma first-quarter revenue up 16% to $15.1 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the first quarter ended March 31, 2010.

11 May 2010

New study to send microorganisms into space

A team of researchers from Rensselaer Polytechnic Institute will send an army of microorganisms into space this week, to investigate new ways of preventing the formation and spread of biofilms, or clusters of bacteria, that could pose a threat to the health of astronauts.

11 May 2010

JHP Pharmaceuticals completes successful GMP/Pre Approval Audit by FDA CDER

JHP Pharmaceuticals' sterile manufacturing site based in Rochester, Michigan completed a successful GMP (Good Manufacturing Practices)/Pre Approval Audit by the U.S. Food and Drug Administration (FDA) drug division (CDER).

11 May 2010

Intercell reports EUR 4.8m revenue, EUR 14.7m net loss for first-quarter 2010

Today, the biotech-vaccine company Intercell AG announced its financial results for Q1 and presented an update on the Company's development programs.

11 May 2010

Poniard Pharmaceuticals reports net loss of $11.9M in first-quarter 2010

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the first quarter ended March 31, 2010.

11 May 2010

Orexigen Therapeutics first-quarter net loss decreases to $14.1 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2010. For the quarter ended March 31, 2010, Orexigen reported a net loss of $14.1 million, or $0.30 per share attributable to common stockholders, as compared to a net loss of $19.3 million, or $0.56 per share attributable to common stockholders, for the first quarter of 2009.

11 May 2010

Dendreon reports $125.7 million net loss for first-quarter 2010

Dendreon Corporation today reported results for the quarter ended March 31, 2010. Revenue for the quarter ended March 31, 2010 was $21,000 compared to $30,000 for the quarter ended March 31, 2009.

11 May 2010

Generex Biotechnology enrolls over 400 subjects in global Phase III study of Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has achieved enrolled of over 400 subjects in its pivotal global Phase III study of its flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product designed to replace prandial injections of insulin.

10 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Accuri Cytometers, eBioscience announce worldwide co-marketing agreement

Accuri Cytometers, Inc., the fastest growing life sciences company marketing and producing revolutionary bench-top flow cytometer systems, and eBioscience, the number two supplier of research flow cytometry reagents, today announced that they have entered into a worldwide co-marketing agreement.

10 May 2010